Upper GI Bleed Admission Order Set: A Comprehensive Clinical Protocol
This order set provides a structured admission protocol for acute upper gastrointestinal bleeding (UGIB), encompassing hematemesis, coffee-ground emesis, melena, and hematochezia with suspected upper GI source. The protocol addresses hemodynamic resuscitation with crystalloids and restrictive transfusion targets, high-dose intravenous proton pump inhibitor therapy, variceal-specific interventions including octreotide and antibiotic prophylaxis, and timely gastroenterology consultation for endoscopic evaluation. Admission criteria include any patient presenting with overt GI bleeding and hemodynamic compromise, significant hemoglobin drop, or high-risk Glasgow-Blatchford Score. The primary therapeutic goals are to achieve hemodynamic stability with MAP ≥65 mmHg, maintain hemoglobin between 7 and 9 g/dL via restrictive transfusion, correct coagulopathy, and facilitate endoscopy within 24 hours of presentation. This protocol is applicable across emergency department, intensive care unit, and step-down ward settings depending on severity stratification.
Assessment & Monitoring
Acute upper gastrointestinal bleeding demands rapid hemodynamic assessment, early risk stratification, and continuous monitoring to detect clinical deterioration. The initial evaluation should focus on confirming the bleeding source as upper GI through history and physical examination, establishing large-bore intravenous access with two 16-gauge or larger peripheral IV lines, and initiating volume resuscitation before any diagnostic procedures. All patients require formal risk scoring using the Glasgow-Blatchford Score at presentation to determine the need for intervention, and the complete Rockall Score after endoscopy to predict rebleeding and mortality risk. Continuous telemetry monitoring is mandatory for patients with hemodynamic instability or active hemorrhage. Nasogastric tube placement may be considered for diagnostic purposes when the source of bleeding is uncertain, though it is not required in all cases and does not improve clinical outcomes when the diagnosis is clear.
Risk Stratification: Glasgow-Blatchford & Rockall Scores
| Parameter | Value | Score | Clinical Implication |
|---|---|---|---|
| BUN (mg/dL) | <18.2 | 0 | Low risk for intervention |
| BUN (mg/dL) | 18.2–22.3 | 2 | Moderate risk |
| BUN (mg/dL) | 22.4–27.9 | 3 | Moderate-high risk |
| BUN (mg/dL) | 28.0–69.9 | 4 | High risk |
| BUN (mg/dL) | ≥70 | 6 | Very high risk |
| Hemoglobin (men, g/dL) | ≥13 | 0 | Normal |
| Hemoglobin (men, g/dL) | 12.0–12.9 | 1 | Mild anemia |
| Hemoglobin (men, g/dL) | 10.0–11.9 | 3 | Moderate anemia |
| Hemoglobin (men, g/dL) | <10 | 6 | Severe anemia |
| SBP (mmHg) | ≥110 | 0 | Hemodynamically stable |
| SBP (mmHg) | 100–109 | 1 | Borderline hypotension |
| SBP (mmHg) | 90–99 | 2 | Hypotension |
| SBP (mmHg) | <90 | 3 | Shock |
| Heart Rate | ≥100 bpm | 1 | Tachycardia |
| Melena | Present | 1 | Active lower source or UGIB |
| Syncope | Present | 2 | Hemodynamic compromise |
| Hepatic Disease | Present | 2 | Portal hypertension risk |
| Heart Failure | Present | 2 | Limited resuscitation reserve |
Laboratory Orders
Initial laboratory evaluation in acute UGIB serves three critical purposes: quantifying the severity of blood loss, identifying coagulopathy requiring correction, and establishing baseline values for serial trending. All STAT labs should be drawn immediately upon presentation, ideally before initiation of fluid resuscitation to obtain an accurate baseline hemoglobin. A type and screen is essential for all patients, and crossmatch of packed red blood cells should be ordered for any patient with hemodynamic instability or hemoglobin below 9 g/dL. Serial hemoglobin monitoring every 6 to 8 hours during the first 24 hours is critical because initial hemoglobin may not reflect the true degree of blood loss due to hemoconcentration from dehydration.
Laboratory Panel Discipline: Trends Beyond Admission
Beyond the standard CBC, CMP, lipase, lactate, and coagulation profile ordered at admission, the highest-yield laboratory discipline in upper gastrointestinal bleeding is serial hemoglobin trending at hours 4, 8, 12, and 24 from admission. A falling hemoglobin trajectory despite ongoing transfusion or stable trajectory above 8 g/dL with active clinical bleeding signals ongoing hemorrhage requiring intervention escalation. Type and crossmatch with at least 2 units cross-matched at admission, with additional cross-matched units available for any patient with hemodynamic instability or active visible bleeding. BUN-to-creatinine ratio above 30 supports upper GI source over lower GI in the patient with melena where source localization is unclear. Liver enzymes plus albumin plus INR establish hepatic synthetic function baseline — critical when considering variceal etiology and procedural anticoagulation reversal. Procalcitonin is reserved for cases with concurrent sepsis features. Repeat coagulation profile every 6 hours during active hemorrhage to monitor dilutional coagulopathy from massive transfusion and guide fresh frozen plasma or prothrombin complex concentrate replacement. Cardiac troponin in the elderly patient with significant blood loss captures demand ischemia that may otherwise be silent during acute resuscitation and influences transfusion threshold decisions.
Medications
Primary Acid Suppression Therapy
Dose: Pantoprazole (Protonix) 80 mg IV bolus, then 8 mg/hr continuous infusion × 72h
Indication: High-risk ulcer stigmata after endoscopic hemostasis (active bleeding, visible vessel, adherent clot). May initiate empirically pre-endoscopy if endoscopy delayed >12 hours. Grade A
Renal adjust: No dose adjustment required for renal impairment. Hepatic impairment (Child-Pugh C): consider reduced dose to 40 mg bolus then 4 mg/hr.
Monitor: Serum magnesium if infusion >72h, hepatic function, signs of C. difficile infection with prolonged use.
Variceal Bleed Protocol
Dose: Octreotide (Sandostatin) 50 mcg IV bolus, then 50 mcg/hr continuous infusion × 3–5 days
Indication: Suspected or confirmed variceal hemorrhage. Initiate immediately when variceal source is suspected (known cirrhosis, portal hypertension, or spider angiomata with GI bleed). Grade A
Renal adjust: No specific renal dose adjustment. Use with caution in dialysis patients due to reduced clearance; consider 25 mcg/hr.
Monitor: Blood glucose q6h (risk of hypoglycemia and hyperglycemia), cardiac rhythm (QTc prolongation risk), abdominal pain or diarrhea, thyroid function with prolonged use >5 days.
Dose: Ceftriaxone (Rocephin) 1 g IV q24h × 7 days
Indication: Antibiotic prophylaxis for all cirrhotic patients with GI bleeding. Reduces bacterial infections, spontaneous bacterial peritonitis, rebleeding, and mortality. Grade A
Renal adjust: No dose adjustment needed for renal impairment. Avoid concurrent calcium-containing IV solutions (risk of ceftriaxone-calcium precipitate).
Monitor: Daily CBC, hepatic panel, signs of biliary sludge with prolonged use, C. difficile-associated diarrhea.
Pre-Endoscopy Prokinetic
Dose: Erythromycin (Erythrocin) 250 mg IV single dose 30–60 min before endoscopy
Indication: Pre-endoscopy gastric emptying to improve endoscopic visualization. Most beneficial when large blood clot burden is expected (active hematemesis, large-volume coffee-ground emesis). Grade B
Renal adjust: No renal adjustment required. Hepatic impairment: use with caution (hepatotoxicity risk); avoid in severe hepatic failure.
Monitor: QTc interval (obtain baseline ECG), infusion site for phlebitis, concurrent QTc-prolonging medications. Infuse over 20–30 minutes to reduce GI side effects.
Supportive & PRN Medications
Dose: Ondansetron (Zofran) 4 mg IV q6h PRN nausea/vomiting
Indication: Nausea or vomiting not attributable to active hemorrhage. Particularly useful post-endoscopy or during octreotide infusion.
Max: 16 mg/day. Reduce to 8 mg/day max in severe hepatic impairment (Child-Pugh C).
Monitor: QTc interval (additive risk with erythromycin or octreotide), constipation, headache.
Dose: Sucralfate (Carafate) 1 g PO QID (1h before meals and at bedtime)
Indication: Mucosal protection after endoscopic hemostasis of gastric or duodenal ulcers. Initiate once patient tolerates oral intake. Grade C
Renal adjust: Use with caution in CrCl <30 mL/min (aluminum accumulation risk). Avoid in dialysis patients.
Monitor: Constipation, drug interactions (separate from PPI, fluoroquinolones, and levothyroxine by ≥2 hours). Bezoar risk with impaired gastric motility.
Anticoagulant Reversal Orders
Warfarin reversal (INR >2.5 with active bleeding):
Vitamin K (phytonadione) 10 mg IV slow infusion over 30 min PLUS 4-factor PCC (Kcentra) 25–50 units/kg IV (dose based on INR: INR 2–4 = 25 units/kg; INR 4–6 = 35 units/kg; INR >6 = 50 units/kg)
Dabigatran reversal: Idarucizumab (Praxbind) 5 g IV as two 2.5 g boluses no more than 15 min apart
Rivaroxaban/Apixaban reversal: Andexanet alfa (Andexxa) low-dose: 400 mg IV bolus at 30 mg/min, then 4 mg/min × 120 min; or high-dose per last dose timing
Monitor: INR q2h after PCC until <1.5, repeat INR at 6h and 24h. For DOAC reversal, anti-Xa levels if available. Watch for thrombotic complications post-reversal.
Medications to AVOID
Admission order set
Upper GI bleeding: key orders around endoscopy
Transfusion when hemodynamically stable
- No cardiovascular disease: transfuse at Hgb <7 g/dL; target Hgb 7–9 g/dL
Variceal bleeding or cirrhosis
- Suspected variceal: octreotide 50 mcg IV bolus, then 50 mcg/hr for 3–5 days
- Cirrhosis with GI bleeding: ceftriaxone 1 g IV q24h
- Suspected variceal: endoscopy within 12 hours; avoid excessive crystalloid
Patient on warfarin
- Hold all anticoagulation; reversal should not delay endoscopy
Before endoscopy
- Active bleeding: baseline ECG, then erythromycin 250 mg IV once, 30–60 min before endoscopy, over 20–30 min
Caution: Not with macrolide allergy, QT prolongation or ventricular arrhythmia, low K or Mg, or interacting drugs (e.g., domperidone, simvastatin, ergotamine, class IA/III antiarrhythmics).
Peptic ulcer at endoscopy
- Forrest Ia, Ib (spurting, oozing) or IIa (nonbleeding visible vessel): endoscopic hemostasis
- Actively bleeding ulcer: epinephrine injection plus contact thermal or mechanical therapy
Caution: Do not use epinephrine injection as monotherapy.
After endoscopy for high-risk ulcer
- Active bleeding, visible vessel or adherent clot: pantoprazole 80 mg IV bolus, then 8 mg/hr × 72 h
Do not order tranexamic acid for any upper GI bleeding indication; stop non‑aspirin NSAIDs.
IV Fluids & Infusions
Hemodynamic resuscitation in acute UGIB should follow a goal-directed approach targeting MAP ≥65 mmHg, heart rate <100 bpm, and urine output ≥0.5 mL/kg/h. Crystalloid resuscitation with lactated Ringer solution is preferred over normal saline due to lower risk of hyperchloremic metabolic acidosis, though normal saline is acceptable when LR is unavailable. Avoid excessive fluid resuscitation in suspected variceal hemorrhage, as aggressive volume expansion can worsen portal pressure and increase rebleeding risk. The restrictive transfusion strategy targeting hemoglobin 7 g/dL has demonstrated superior outcomes compared to liberal transfusion in hemodynamically stable patients, with reductions in rebleeding, mortality, and adverse events. Massive transfusion protocol should be activated when estimated blood loss exceeds 1500 mL, ongoing hemorrhage requires more than 4 units pRBC in 1 hour, or hemodynamic instability persists despite 2 liters of crystalloid.
- Lactated Ringer (LR) 500 mL IV bolus over 15–30 min; repeat up to 2 L total as needed to achieve MAP ≥65 mmHg
- If Hgb <7 g/dL: Transfuse 1 unit pRBC over 90–120 min (or 15–30 min in acute hemorrhagic shock); target Hgb 7–9 g/dL
- If massive hemorrhage protocol activated: pRBC:FFP:platelets in 1:1:1 ratio; notify blood bank for uncrossmatched O-negative release
- For variceal bleed: Limit crystalloid to 1 L; prioritize blood products over crystalloid to avoid portal pressure elevation
- Reconstitute pantoprazole 80 mg vial with 10 mL NS; further dilute in 100 mL NS bag (concentration: 0.8 mg/mL)
- Administer 80 mg IV bolus over 15 minutes via dedicated peripheral or central line
- Immediately follow bolus with continuous infusion at 8 mg/hr (10 mL/hr of 0.8 mg/mL solution); prepare new bag q10h
- Protect from light. Compatible with NS and D5W only. Do NOT mix with other IV medications or blood products.
- Add Octreotide 250 mcg (1 mL of 500 mcg/mL vial) to 250 mL NS (final concentration: 1 mcg/mL)
- Administer 50 mcg IV bolus over 3–5 minutes (50 mL of 1 mcg/mL solution or from stock vial)
- Start continuous infusion at 50 mcg/hr (50 mL/hr of 1 mcg/mL concentration) for 3–5 days
Admission timeline
Acute upper GI bleeding
At presentation
IV access, labs, first drugs
- Two 16-gauge or larger IVs; STAT labs, type and screen; Glasgow-Blatchford Score; GI consult ≤2 h
- Variceal suspicion (incl. known cirrhosis): octreotide, ceftriaxone
- Hold anticoagulants; do not delay endoscopy for reversal
Before any diagnostic procedure
Hemodynamic resuscitation
- Unstable: LR 500 mL IV boluses to MAP ≥65 mmHg, up to 2 L (≤1 L if variceal suspicion)
- Still unstable and bleeding: ICU; massive transfusion protocol (no FFP if variceal suspicion)
- Stable: transfuse at Hgb <7 g/dL; cardiovascular disease: ≤8 g/dL
30–60 min before endoscopy
Erythromycin 250 mg IV
- Active bleeding: single dose over 20–30 min, after a baseline ECG
Caution: Do not give with QT prolongation, prior ventricular arrhythmia, macrolide allergy, low K or Mg, or interacting drugs.
Within 24 h of presentation
Endoscopy
- Variceal suspicion: ≤12 h
- Unstable despite resuscitation: as soon as safely possible
After endoscopy
PPI for ulcers, rebleeding plan
- Ulcer with endoscopic hemostasis or adherent clot: pantoprazole 80 mg IV, then 8 mg/h for 72 h
- Nonvariceal rebleeding: repeat endoscopy; if it fails, consider embolization, then surgery
At discharge
Criteria and plan
- Hgb ≥7 g/dL, varying <0.5 g/dL on two consecutive checks ≥12 h apart; cardiovascular disease: transfuse at ≤8 g/dL
- Oral diet tolerated ≥24 h; ulcer bleeding: on oral PPI ≥12 h
- Avoid NSAIDs except secondary-prevention aspirin; antithrombotic plan; treat H. pylori if positive
Conditional Orders
Conditional orders define the branching logic for managing clinical deterioration, unexpected laboratory findings, and escalation scenarios in acute UGIB. Each condition below represents a measurable clinical trigger paired with a specific intervention including drug name, dose, and route. These orders should be entered in the electronic medical record as standing conditional orders so that nursing staff can execute them without delay while awaiting physician reassessment. Early activation of the massive transfusion protocol and timely GI consultation are the two most time-critical conditional actions in this order set.
ICU transfer: MAP <65 mmHg requiring vasopressor support, need for mechanical ventilation or airway protection, massive transfusion protocol activation (>4 units pRBC in 1 hour), or persistent hemodynamic instability after 2 L crystalloid and 2 units pRBC.
Interventional radiology consult: Rebleeding after two endoscopic hemostasis attempts, anatomically inaccessible bleeding source, or endoscopic failure to achieve hemostasis.
Surgery consult: Uncontrolled hemorrhage despite endoscopic and IR intervention, perforation complicating endoscopic therapy, or massive hemorrhage from gastric malignancy.
Hepatology / Transplant referral: Refractory variceal bleeding despite band ligation and pharmacotherapy; consider TIPS (transjugular intrahepatic portosystemic shunt) for salvage therapy.
- Optimal timing of anticoagulation resumption after UGIB hemostasis in patients with mechanical heart valves or recent VTE
- Role of pre-endoscopy PPI infusion versus bolus dosing in patients who undergo endoscopy within 6 hours of presentation
- Benefit of erythromycin prokinetic when endoscopy is performed within 4 hours of last emesis episode
Step-Down & Discharge
Step-Down to Ward Criteria
- Hemodynamically stable for ≥12 hours: SBP ≥100 mmHg, HR <100 bpm without vasopressor support
- No evidence of rebleeding for ≥24 hours: stable Hgb (variation <1 g/dL over 12h), no recurrent hematemesis or melena
- Afebrile (<38.0°C) with no signs of infection for ≥12 hours
- Endoscopic hemostasis achieved with Forrest Ib or better classification on follow-up assessment
- Off vasopressors and continuous PPI infusion transitioned to intermittent IV or oral PPI
Discharge Criteria
- Hemoglobin stable (≥7 g/dL, variation <0.5 g/dL) on two consecutive checks ≥12 hours apart
- Tolerating oral diet without nausea, vomiting, or recurrent GI symptoms for ≥24 hours
- Successfully transitioned from IV to oral PPI for ≥12 hours
- Anticoagulation plan documented: timing of restart, bridging strategy if needed, and outpatient monitoring plan
- GI follow-up endoscopy scheduled within 6–8 weeks for ulcer healing assessment and H. pylori status
- Patient education completed: alarm symptoms (recurrent hematemesis, melena, lightheadedness), medication adherence, NSAID avoidance, alcohol cessation counseling if applicable
Discharge Medications
| Drug | Dose | Duration | Follow-up Labs |
|---|---|---|---|
| Pantoprazole (Protonix) | Pantoprazole 40 mg PO BID | 8–12 weeks | Repeat EGD at 8 weeks for ulcer healing; Mg level if >3 months |
| H. pylori eradication (if positive) | PPI BID + Clarithromycin 500 mg BID + Amoxicillin 1000 mg BID × 14 days | 14 days (start after acute phase resolves) | H. pylori stool antigen 4 weeks after completing treatment (off PPI ≥2 weeks) |
| Ferrous sulfate | Ferrous sulfate 325 mg PO daily (65 mg elemental iron) | 3–6 months or until ferritin >100 | CBC, iron studies, ferritin at 4 weeks and 3 months |
| Sucralfate (if post-ulcer) | Sucralfate 1 g PO QID × 4–8 weeks | 4–8 weeks | None routinely; renal function if CKD |
You were admitted for bleeding in your upper digestive tract. You received an intravenous medication called pantoprazole to reduce stomach acid and help your stomach heal. You may have also received blood transfusions and a procedure called an endoscopy to find and treat the bleeding source. At discharge, you will continue taking pantoprazole by mouth twice daily for 8 to 12 weeks. If a bacteria called H. pylori was found, you will also take antibiotics for 14 days. Take iron supplements daily to rebuild your blood counts. Avoid all NSAIDs (ibuprofen, naproxen, aspirin unless prescribed for your heart), limit alcohol, and return immediately if you vomit blood, notice dark or tarry stools, feel lightheaded, or pass out.
Quick Reference Card
Protocol Experience: Where the Order Set Slips and How Experienced Clinicians Adjust
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)The endoscopist is asleep at home, the stomach is filling with clot, and the ward waits for morning, which makes upper gastrointestinal bleeding order sets the field where the most consistent practice gap they correct is the failure to administer pre-endoscopic erythromycin in any patient with active UGIB. The 30-60 minute window between admission decision-to-endoscope and the actual procedure is wasted in most order sets when erythromycin 250 mg IV could be improving endoscopic visualization meaningfully — a free, simple, evidence-aligned intervention that nonetheless gets routinely omitted.
Where Bundles Slip in Practice
Pre-endoscopic erythromycin 250 mg IV administered 30-60 minutes before endoscopy is the under-utilized intervention experienced practitioners add to every UGIB order set. The prokinetic effect clears stomach contents and active blood, improves mucosal visualization, reduces the need for second-look endoscopy, and is essentially free in cost and complications. Yet most order sets they encounter in referrals do not include it, and the endoscopist arrives at a stomach full of blood and clot that delays definitive treatment.
Re-Assessment Rhythm
Glasgow-Blatchford Score at admission triages outpatient candidate (GBS 0-1) from admission, vitals every hour for the first 8 hours then every 2 hours through hour 24, hemoglobin every 4 hours for the first 24 hours with type-and-screen renewal as needed. The trajectory of these markers — not single timepoint values — drives the escalation decisions. A patient whose hemoglobin is dropping despite transfusion is rebleeding, and IR consultation is initiated rather than another unit of blood.
Escalation Tripwire
Failed endoscopic hemostasis or rebleeding after initial endoscopic therapy triggers immediate interventional radiology consultation for selective transcatheter embolization, not surgical referral first. IR embolization has supplanted surgery as the first-line salvage after failed endoscopy in non-variceal UGIB, with lower morbidity, faster intervention, and equivalent or better outcomes in modern series. Surgery is reserved for patients in whom IR embolization is not anatomically feasible or has failed.
Variceal Doctrine
Variceal suspicion — established cirrhosis, known portal hypertension, prior variceal bleed, ascites, splenomegaly — triggers immediate ceftriaxone 1 g IV plus octreotide drip (50 mcg IV bolus + 50 mcg/hour infusion) even before endoscopic confirmation. The prophylactic antibiotic reduces bacterial peritonitis and mortality in cirrhotic UGIB; octreotide reduces splanchnic blood flow and aids hemostasis. Both can be initiated empirically and discontinued if non-variceal etiology is confirmed.
Illustrative Scenario
A man in his late sixties presented to the emergency department with 24 hours of intermittent melena, lightheadedness, and one episode of coffee-ground emesis. Vital signs showed blood pressure 92/56, heart rate 118, oxygen saturation 96% on room air. Hemoglobin was 7.2 g/dL on arrival, BUN 48 mg/dL (creatinine 1.0, ratio 48 suggesting upper GI source), INR 1.0, platelets 142. Glasgow-Blatchford Score was 11 (high risk admission). The treating clinicians initiated restrictive transfusion targeting hemoglobin 7-9 g/dL given absence of cardiac disease, IV pantoprazole 80 mg bolus followed by 8 mg/hour infusion, ondansetron for nausea, and crucially erythromycin 250 mg IV administered 45 minutes before the planned endoscopy. Upper endoscopy performed within 6 hours of admission revealed a 12 mm duodenal bulb ulcer with Forrest IIa visible vessel — high-risk stigmata. Combination endoscopic hemostasis was performed with epinephrine injection, hemoclip placement on the visible vessel, and adjacent bipolar coagulation. The PPI infusion was continued for 72 hours then transitioned to oral pantoprazole 40 mg twice daily. Helicobacter pylori testing was positive and eradication therapy initiated. He was discharged on hospital day 4 with no rebleeding and a planned 4-week follow-up for H. pylori eradication confirmation.
Practice Protocol Adjustments to the Standard Order Set
- Erythromycin 250 mg IV 30-60 minutes before any planned endoscopy for active UGIB. Prokinetic effect clears stomach contents, improves mucosal visualization, reduces second-look endoscopy need. Free intervention that most order sets routinely omit.
- Restrictive transfusion targeting hemoglobin 7-9 g/dL (Hgb <7 trigger), with <8 g/dL threshold in active cardiac disease only. Liberal transfusion (Hgb <9) historical pattern is associated with increased rebleeding and mortality per Villanueva 2013 NEJM and replication studies.
- Variceal suspicion triggers immediate empiric ceftriaxone 1 g IV + octreotide drip (50 mcg bolus + 50 mcg/hour) before endoscopic confirmation. Prophylactic antibiotic reduces SBP and mortality in cirrhotic UGIB; octreotide reduces splanchnic blood flow. Both discontinued if non-variceal etiology confirmed.
- Failed endoscopic hemostasis: IR embolization first-line over surgery. Selective transcatheter embolization produces lower morbidity, faster intervention, and equivalent or better outcomes than surgical salvage in non-variceal UGIB. Surgery reserved for IR-infeasible or IR-failed cases.
Frequently Asked Questions
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ACG 2021 Clinical Guideline: Upper GI and Ulcer Bleeding (American Journal of Gastroenterology · 2021)